Implications of Aducanumab’s FDA Approval
Insights - The biotech market (XBI) is up over 4% today on news that the FDA approved Biogen’s aducanumab for Alzheimer’s Disease. It is the first new … Continue Reading
PremiumAuthor Archives: D Mero
Magenta’s MGTA-145 ASCO Data Weaker Than Initially Reported
Insights - Magenta (MGTA) released more patient data at ASCO from their Phase 2 in mobilizing Multiple Myeloma patients. Remember, a few weeks ago, the abstract had data on 10 Multiple Myeloma patients … Continue Reading
Premium
Magenta’s MGTA-145 Mobilizes Multiple Myeloma Patients
Insights - Magenta reported preliminary data from their Phase 2 in mobilizing Multiple Myeloma patients and it was phenomenal. Concurrently, with the data announcement, Magenta also closed a $86M financing with … Continue Reading
Premium
NovaVax Faces Delays on All Fronts
Research - Novavax (NVAX) reported Q1 earnings yesterday after market and it was an overall disappointing update. The company was burdened with delays on all fronts, including US Phase … Continue Reading
PremiumMagenta Conditioning Peer Goes Public Via SPAC
Insights - Yesterday, Magenta (MGTA) competitor Jasper merged with SPAC company Amplitude Healthcare (AMHC). As part of transaction, Jasper will have a $490M valuation with a cash … Continue Reading
Premium
Biden’s Covid IP Waiver Is a PR Stunt
Insights - Yesterday, President Biden backed a proposed waiver for COVID-19 vaccine intellectual property rights. This would allow generic manufacturing of the vaccines and increase vaccine accessibility … Continue Reading
PremiumNovaVax News Flow Expected to Continue
Insights - It has been an eventful week for Novavax (NVAX), and we believe the news flow will spill over into next week. Biden’s Speech Included NovavaxOn … Continue Reading
Premium